

Special Issue

Cancer Vaccines: Current Advances, Clinical Applications, and Future Directions

Message from the Guest Editors

Anticancer vaccines represent another approach to tumor immunotherapy. Preventive vaccines, such as anti-HPV or -HBV, proved their efficacy in reducing the risk of cancer development. However, therapeutic vaccines aim to reshape one's immunological profile to increase cytotoxic and anticancer properties to treat an already present tumor. Introducing mRNA, DNA, neoantigens, or stimulated dendritic cells promotes the presentation of cancer antigens, thus enhancing CD8+ T cell-mediated anticancer effects. Implementing anticancer therapeutic vaccines should broaden the treatment potential in cancers with difficulties in developing targeted therapies. Furthermore, it could improve the anticancer activity of other oncological therapeutics or reduce treatment resistance. This Special Issue aims to present original research papers and reviews that provide updates and discuss novel opportunities for anticancer therapeutic vaccines. Manuscripts and reviews in the following research areas are encouraged: nucleic acid vaccines, cellular vaccines, viral vaccines, preclinical and clinical studies, and translational medicine.

Guest Editors

Dr. Paulina Niedźwiedzka-Rystwej
Dr. Kajetan Kiełbowski
Dr. Rafał Becht

Deadline for manuscript submissions

31 December 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/234965

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).